Plus Therapeutics, Inc. to Present at the 9th Annual Gateway Conference on September 10, 2020
September 03 2020 - 07:00AM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today
announced that it has been invited to present at the 9th Annual
Gateway Conference, which is being held virtually on September
9-10, 2020.
Plus Therapeutics, Inc. management is scheduled to
present on Thursday, September 10 at 3.30 p.m. eastern time, with
one-on-one meetings to be held throughout the conference. The
presentation will be webcast live and available for replay at
https://www.webcaster4.com/Webcast/Page/2492/37150.
To receive additional information, request an invitation or to
schedule a one-on-one meeting, please email
conference@gatewayir.com.
About the Gateway Conference The 9th Annual
Gateway Conference is an invite-only conference presented by
Gateway Investor Relations, a full-service financial communications
firm. The conference was created to bring together the most
compelling companies with the nation’s top institutional investors
and analysts. This year’s event features a long list of companies
from a number of growth industries, including technology, business
and financial services, consumer, digital media, clean technology
and life sciences. The format has been designed to give attendees
direct access to senior management via company presentations,
Q&A sessions and one-on-one meetings. Follow the Gateway
Conference on Twitter and join the conversation using the
#GatewayIRConference hashtag. For more information, visit
gatewayir.com/conference.
About Plus Therapeutics, Inc.Plus Therapeutics
(Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose
radiotherapeutic portfolio is concentrated on
nanoliposome-encapsulated radionuclides for several cancer targets.
Central to the Company’s drug development is a unique
nanotechnology platform designed to reformulate, deliver and
commercialize multiple drugs targeting rare cancers and other
diseases. The platform is designed to facilitate new delivery
approaches and/or formulations of safe and effective, injectable
drugs, potentially enhancing the safety, efficacy and convenience
for patients and healthcare providers. More information may be
found at plustherapeutics.com and respect-trials.com.
Cautionary Statement Regarding Forward-Looking
StatementsThis press release contains certain statements
that may be deemed “forward-looking statements” within the meaning
of U.S. securities laws. All statements, other than statements of
historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate and similar
expressions or future conditional verbs such as will, should,
would, could or may occur in the future are forward-looking
statements. Such statements are based upon certain assumptions and
assessments made by our management in light of their experience and
their perception of historical trends, current conditions, expected
future developments and other factors they believe to be
appropriate. These statements include, without limitation,
statements about: the Company’s potential to facilitate new
delivery approaches and/or formulations of safe and effective,
injectable drugs, potentially enhancing the safety, efficacy and
convenience for patients and healthcare providers; the Company’s
potential to develop drug candidates currently in its product
pipeline; and the Company’s potential to develop additional drugs
outside of its current pipeline. The forward-looking statements
included in this press release are subject to a number of
additional material risks and uncertainties, including but not
limited to: the risk that the Company is not able to successfully
develop product candidates that can leverage the U.S. FDA’s
accelerated regulatory pathways; and the risks described under the
heading “Risk Factors” in the Company’s Securities and Exchange
Commission filings, including in the Company’s annual and quarterly
reports. There may be events in the future that the Company is
unable to predict, or over which it has no control, and its
business, financial condition, results of operations and prospects
may change in the future. The Company assumes no responsibility to
update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made unless the
Company has an obligation under U.S. federal securities laws to do
so.
Contact:Plus Therapeutics,
Inc. Andrew Sims VP – Chief Financial Officer,
Investor Relations Phone: +1.619.333.4150
Email: ir@plustherapeutics.com Corporate
Website: plustherapeutics.comClinical
Website: respect-trials.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Feb 2024 to Mar 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Mar 2023 to Mar 2024